Skip to main content
Equibles

David Margrave

CFO

Lantern Pharma Inc. (LTRN)

Equibles does not estimate personal net worth.

Get an email with a short summary when Lantern Pharma Inc. publishes a filing, an earnings call transcript or a press release.

Get LTRN alerts

About David Margrave

David Margrave is recorded as CFO at Lantern Pharma Inc. (LTRN). The newest filing on record that lists David Margrave as CFO at Lantern Pharma Inc. (LTRN) is dated October 19, 2026. The proxy statement of Lantern Pharma Inc. reports total compensation of $752,886 for David Margrave in fiscal 2024, including a base salary of $413,800. Disclosed compensation is on record for 6 fiscal years. David Margrave has spoken on 21 earnings calls across 1 company, most recently for Lantern Pharma Inc. on August 14, 2026. Lantern Pharma Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Lantern Pharma Inc. includes Panna Sharma (CEO and Board Member) and Lee T. Schalop, M.D. (Board Member).

David Margrave on recent calls

“I'll now share some financial highlights from our second quarter into June 30, 2026.”
CFO, Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET ·
“I'll now share some financial highlights from our fourth quarter and full year ended December 31, 2025. I'll start with a review of the fourth quarter. Our general and administrative expenses were approximately $1.5 million for the fourth quarter of 2025, compared to approximately $1.6 million in the prior year period.”
CFO, Lantern Pharma Inc. Q4 FY2025 Earnings Call ·
“I'll now share some financial highlights from our first quarter 2025 ended March 31, 2025. Our general and administrative expenses were approximately $1.51 million for the first quarter of 2025 compared to approximately $1.48 million in the prior year period.”
CFO, Lantern Pharma Inc. Q1 FY2025 Earnings Call ·
“I will now share some financial highlights from our third quarter ended September 30, 2024. We recorded a net loss of approximately $4.5 million for the third quarter of 2024, or $0.42 per share, compared to a net loss of approximately $3.2 million, or $0.29 per share, for the third quarter of 2023.”
CFO, Lantern Pharma Inc. Q3 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Lantern Pharma Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 Lantern Pharma Inc. (LTRN) $413,800 $752,886
2023 Lantern Pharma Inc. (LTRN) $353,290 $442,680
2022 Lantern Pharma Inc. (LTRN) $332,667 $394,359
2021 Lantern Pharma Inc. (LTRN) $300,000 $561,315
2020 Lantern Pharma Inc. (LTRN) $225,154 $1,160,962
2019 Lantern Pharma Inc. (LTRN) $97,019 $97,019

Recent activity

Show 9 earlier activities